No Recent Domestic Digital Health Company Filed IPO with Financing Over RMB 225 Million in the Past 15 Days

The content of this article is processed and compiled based on monitoring data from the VCBeat Blue Book.

This issue of the Little Blue Book comprises 24 pages and covers the following content:

Note: The full version of [VCBeat Blue Book] will be regularly shared with members in the VCBeat WeChat discussion group. To join the VCBeat WeChat discussion group, scan the QR code to apply >>>

【p.s.】Click here if you're a big spender【VCBeat Blue Book_No.11】Purchase Full Edition（¥9.9）

According to data compiled by VCBeat, the total financing amount in China’s digital health sector exceeded RMB 200 million between November 26 and December 8, 2016. The funded projects are summarized as follows:

Beideng Medical is an e-commerce platform for medical device procurement, providing one-stop supply chain services for related medical products to small and medium-sized medical device distributors. It is a website under Nanjing Beideng Biotechnology Co., Ltd. Beideng Medical primarily procures from upstream medical device manufacturers and serves downstream small and medium-sized medical device distributors as well as select private healthcare institutions. Currently, Beideng Medical has established partnerships with more than 300 branded medical device manufacturers, including Mindray, CR Wandong, Yuwell, Sinocare, Philips, and 3M.

In June 2015, Beden Medical secured RMB 30 million in Pre-A round financing, with Fenxiang Investment as the investor. In November 2016, Beden Medical raised RMB 65 million in Series A financing, led by Zhongwei Fund, Oriental Fortune Capital, and Puhua Capital (Puhua Guzhou Capital). Following this funding round, Beden Medical began providing financial products to healthcare institutions, officially launching its Beden Finance business.

Beijing Zhikang Boyao Oncology Medical Research Co., Ltd.Established inNovember 2012，is a healthcare services company that provides personalized treatment plans for cancer patients, through its unique I-GraftTM Technology Platform Identifies the Most Effective Treatment Regimens for Cancer Patients。Dr. Chen Yiyou is the Founding Partner and Chairman of Beijing Zhikang Boyao Oncology Research Co., Ltd., heHe also serves as Chairman and President of Zhejiang Nuohui Biotechnology Co., Ltd.. Prior to founding ZhiKangBoYao, Dr. Chen was at Crown Bioscience, a U.S.-based company headquartered in Silicon Valley (Crown Bioscience Inc.) Co-founder and Chief Scientist.2015Year1In [Month], Zhikang Boyao obtained2500ten thousand yuanAround of financing, with Legend Capital and Lenovo Star as investors.2016Year11In [Month], Zhikang Boyao received investment from Panlin Capital.Bround of financing, with the specific amount undisclosed.

Beijing HaoXinqing Mobile Medical Technology Co., Ltd.Established in2016Year4Month,is a mobile healthcare platform specializing in mental health, dedicated to providing internet-based medical services in the field of psychiatry and psychology. The platform primarily offers services such as academic research and learning, private psychological counseling, personal physician services, real-time information updates, and medical record management.Currently,HaoXinqing has over registered users50Ten Thousand，Platform already availableApprox.110,000 Psychiatrists from Public Hospitals Across China Have Joined。2016Year12Month, Good Mood Obtained5000RMB 10,000 in angel round financing, with Enhua Pharmaceutical as the investor.

Cilu Medical, established in 2010, is a pioneer in pediatric care dedicated to providing comprehensive mid-to-high-end children’s healthcare services. Leveraging its own team of physicians and nurses, the company partners with multiple high-end private medical institutions in Beijing and Shanghai to deliver management expertise. Wang Yuan, Founder and CEO of Cilu Medical, stated that after six years of deep engagement in the pediatric sector, the company has accumulated extensive experience in understanding customer needs and developing targeted pediatric service products. In December 2016, Cilu Medical secured tens of millions of RMB in Pre-A series financing from Qingrui Ventures. Following this round of funding, Cilu Medical will further expand its self-operated network of child healthcare services.

Beijing Hope Genomics Co., Ltd. was established in June 2014 as China’s first third-generation sequencing research service company, co-founded by Professor Wang Depeng and Professor Wang Kai. The team leverages innovative applications of cutting-edge technologies to enhance the accuracy and detection rates of genetic testing for hereditary diseases, providing one-stop big data solutions to medical professionals on the front lines of diagnosis and treatment.

Currently, Beijing Hope Genomics operates two major brands, “Future Genomics” and “Hope Genomics,” catering to research and clinical users, respectively. On December 5, 2016, Beijing Hope Genomics announced the completion of its Series A financing round, led by Matrix Partners China and SAIF Partners, with participation from Tsing Capital. The total amount raised was in the hundreds of millions of RMB. This funding will be used to promote the application and widespread adoption of third-generation sequencing technology.

Author: VCBeat. Please credit the WeChat Official Account when reposting.VBResearch2016

↓↓↓